| A comprehensive review on miR-146a molecular mechanisms in a wide spectrum of immune and non-immune inflammatory diseases SS Mortazavi-Jahromi, M Aslani, A Mirshafiey Immunology Letters 227, 8-27, 2020 | 52 | 2020 |
| Introduction of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression A Mirshafiey, M Taeb, SS Mortazavi-Jahromi, F Jafarnezhad-Ansariha, ... Pharmacological Reports 69 (5), 1067-1072, 2017 | 36 | 2017 |
| Cytokine storm in the pathophysiology of COVID-19: possible functional disturbances of miRNAs M Aslani, SS Mortazavi-Jahromi, A Mirshafiey International Immunopharmacology 101, 108172, 2021 | 35 | 2021 |
| Pharmacological effects of β-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-κB gene expression, as target molecules in inflammatory reactions SS Mortazavi-Jahromi, MM Jamshidi, A Farazmand, Z Aghazadeh, ... Pharmacological Reports 69 (3), 479-484, 2017 | 34 | 2017 |
| An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs M Taeb, SS Mortazavi-Jahromi, A Jafarzadeh, MR Mirzaei, A Mirshafiey Biomedicine & Pharmacotherapy 90, 262-267, 2017 | 24 | 2017 |
| Immunopharmacological effect of β‐d‐mannuronic acid (M2000), as a new immunosuppressive drug, on gene expression of miR‐155 and its target molecules (SOCS1, SHIP1) in a … SS Mortazavi‐Jahromi, M Aslani, S Omidian, A Ahmadzadeh, ... Drug development research 81 (3), 295-304, 2020 | 23 | 2020 |
| Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis MJ Fattahi, H Ahmadi, F Jafarnezhad-Ansariha, SS Mortazavi-Jahromi, ... Biomedicine & Pharmacotherapy 100, 495-500, 2018 | 23 | 2018 |
| Two Faces of LRBA Deficiency in Siblings: Hypogammaglobulinemia and Normal Immunoglobulin Levels. G Azizi, H Abolhassani, S Habibi, T Rahamooz, H Mohammadi, ... Journal of investigational allergology & clinical immunology 28 (1), 48-50, 2018 | 23 | 2018 |
| The circulating T helper subsets and regulatory T cells in patients with common variable immunodeficiency with no known monogenic disease G Azizi, A Mirshafiey, H Abolhassani, R Yazdani, F Jafarnezhad-Ansariha, M ... J Investig Allergol Clin Immunol 28 (3), 172-181, 2018 | 23* | 2018 |
| Efficient Roles of miR-146a in Cellular and Molecular Mechanisms of Neuroinflammatory Disorders: An Effectual Review in Neuroimmunology M Aslani, SS Mortazavi-Jahromi, A Mirshafiey Immunology Letters 238, 1-20, 2021 | 22 | 2021 |
| Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway SS Mortazavi-Jahromi, A Farazmand, N Motamed, SS Navabi, ... International Immunopharmacology 55, 323-329, 2018 | 22 | 2018 |
| Anti-diabetic effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on insulin production, blood glucose, and inflammatory markers in the … SS Mortazavi-Jahromi, S Alizadeh, MH Javanbakht, A Mirshafiey Archives of physiology and biochemistry 125 (5), 435-440, 2018 | 21 | 2018 |
| A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-d-mannuronic acid in rheumatoid arthritis patients H Ahmadi, AR Jamshidi, F Gharibdoost, M Mahmoudi, N Rastkari, ... Inflammopharmacology 26 (3), 737-745, 2018 | 21 | 2018 |
| The role of β-d-mannuronic acid, as a new non-steroidal anti-inflammatory drug on expression of miR-146a, IRAK1, TRAF6, NF-κB and pro-inflammatory cytokines following a … SS Mortazavi-Jahromi, A Ahmadzadeh, Z Rezaieyazdi, M Aslani, ... Immunopharmacology and Immunotoxicology 42 (3), 228-236, 2020 | 19 | 2020 |
| International multicenter randomized, placebo-controlled phase III clinical trial of β-d-mannuronic acid in rheumatoid arthritis patients Z Rezaieyazdi, A Farooqi, H Soleymani-Salehabadi, A Ahmadzadeh, ... Inflammopharmacology 27 (5), 911-921, 2019 | 17 | 2019 |
| Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property. A Mirshafiey, SS Mortazavi-Jahromi, M Taeb, S Cuzzocrea, E Esposito Recent patents on inflammation & allergy drug discovery 12 (2), 162-168, 2018 | 17 | 2018 |
| Inhibitory effect of G2013 molecule as a novel immunomodulatory agent, on miR-155 gene expression in HEK-Blue hTLR4 cell line SS Mortazavi-Jahromi, MM Jamshidi, M Yousefi, SS Navabi, N Motamed, ... European Journal of Inflammation 14 (2), 86-92, 2016 | 16 | 2016 |
| Anti-angiogenesis effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive properties under experimental model. M Rastegari-Pouyani, A Mostafaie, K Mansouri, SS Mortazavi-Jahromi, ... Clinical and experimental pharmacology & physiology 45 (4), 370-376, 2017 | 15 | 2017 |
| Effect of β-d-mannuronic acid (M2000) on oxidative stress enzymes’ gene using healthy donor peripheral blood mononuclear cells for evaluating the anti-aging property M Taeb, A Jafarzadeh, SS Mortazavi-Jahromi, N Zainodini, MR Mirzaei, ... Current drug discovery technologies 16 (3), 265 - 271, 2018 | 13 | 2018 |
| Cardioprotective effect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model SS Mortazavi-Jahromi, S Alizadeh, MH Javanbakht, A Mirshafiey Immunopharmacology and immunotoxicology 40 (4), 284-289, 2018 | 13 | 2018 |
